Website
N/ATelephone
61.2.9209.4037
Address
4 Cornwallis Street National Innovation Centre Eveleigh, New South Wales (NSW) 2015
Description
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. It engages in research and development and clinical stage evaluation of its portfolio of novel radiopharmaceuticals products. The company was founded by Matthew Harris on April 8, 2010 and is headquartered in Eveleigh, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 1.63 - 8.98
Trade Value (12mth)
AU$1,826,250.00
1 week
-6.34%
1 month
-30.7%
YTD
145.78%
1 year
206.87%
All time high
8.98
EPS 3 yr Growth
289.20%
EBITDA Margin
N/A
Operating Cashflow
-$43m
Free Cash Flow Return
-40.10%
ROIC
-39.30%
Interest Coverage
N/A
Quick Ratio
19.00
Shares on Issue (Fully Dilluted)
281m
HALO Sector
Healthcare
Next Company Report Date
20-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.38
Date | Announcements |
---|---|
06 December 24 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
06 December 24 |
Cleansing Notice
×
Cleansing Notice |
06 December 24 |
S&P DJI Announces December 2024 Quarterly Rebalance
×
S&P DJI Announces December 2024 Quarterly Rebalance |
28 November 24 |
Last patient assessment completed for SARTATE trial
×
Last patient assessment completed for SARTATE trial |
26 November 24 |
Change of Director's Interests - All Directors
×
Change of Director's Interests - All Directors |
26 November 24 |
First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA
×
First 2 participants dosed with Cu-64 SAR-bisPSMA in Co-PSMA |
25 November 24 |
Notification regarding unquoted securities - CU6
×
Notification regarding unquoted securities - CU6 |
20 November 24 |
AGM MD Presentation
×
AGM MD Presentation |
20 November 24 |
Chairperson Address AGM
×
Chairperson Address AGM |
20 November 24 |
Results of Meeting
×
Results of Meeting |
18 November 24 |
Head-to-head IIT with SAR-bisPSMA
×
Head-to-head IIT with SAR-bisPSMA |
11 November 24 |
Clarity and Nucleus RadioPharma sign MSA
×
Clarity and Nucleus RadioPharma sign MSA |
05 November 24 |
CMS final rule on radio-diagnostic reimbursement policy
×
CMS final rule on radio-diagnostic reimbursement policy |
01 November 24 |
Notification regarding unquoted securities - CU6
×
Notification regarding unquoted securities - CU6 |
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 October 24 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
28 October 24 |
Cleansing Notice
×
Cleansing Notice |
18 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
17 October 24 |
Application for quotation of securities - CU6
×
Application for quotation of securities - CU6 |
17 October 24 |
Cleansing Notice
×
Cleansing Notice |
16 October 24 |
Copper-67 SAR-bisPSMA updates
×
Copper-67 SAR-bisPSMA updates |
14 October 24 |
Michelle Parker Promoted to CEO
×
Michelle Parker Promoted to CEO |
14 October 24 |
Positive guidance from the US FDA on Phase III trial
×
Positive guidance from the US FDA on Phase III trial |
08 October 24 |
Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA
×
Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA |
04 October 24 |
Change of Director's Interest Notices - AT CB CR TR MP
×
Change of Director's Interest Notices - AT CB CR TR MP |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.